Clinical Scorecard: Comprehensive Evaluation of miR-15a-5p, miR-20a-5p, and miR-33b-3p Reveals EGR2-Related Biomarkers in Multiple Myeloma
At a Glance
Category
Detail
Condition
Key Mechanisms
Involvement of microRNAs (miR-15a-5p, miR-20a-5p, miR-33b-3p) in disease pathogenesis and regulation of EGR2, with emphasis on their roles in tumor suppression and progression.
Target Population
Care Setting
Key Highlights
Include a highlight on the role of miR-33b in cancer development.
Guideline-Based Recommendations
Diagnosis
Management
Focus on achieving minimal residual disease and negative complete remission, while also considering emerging therapies and clinical trials.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Current treatments include proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
Clinical Best Practices
Include regular monitoring of treatment response through imaging and biomarker assessment.
